title: [Louse-borne-relapsing-fever in refugees from the Horn of Africa; a case series of 25 patients].
abstract: Background | Relapsing fever is divided into tick borne relapsing fever (TBRF) and louse borne relapsing fever (LBRF). This report describes 25 refugees from East Africa who were diagnosed to suffer from LBRF within a period of 6 month only at a single hospital in Munich / Germany. Material & Methods | The aim was to point out common clinical features as well as laboratory findings and clinical symptoms before and after initiation of treatment in 25 patients with louse borne relapsing fever (LBRF) who were diagnosed and treated at Klinikum München Schwabing from August 2015 to January 2016. To the best of our knowledge this is the largest case series of LBRF in the western world for decades. Main focus of the investigation was put on clinical aspects. Results | All 25 patients suffered from acute onset of high fever with chills, headache and severe prostration. Laboratory analysis showed high CRP and a marked thrombocytopenia. A Giemsa blood stain was procured immediately in order to look for malaria. In the blood smear spirochetes with typical shape and aspect of borrelia species could be detected.The further PCR analysis confirmed infection with Borrelia recurrentis. Treatment with Doxycycline was started forthwith. The condition improved already on the second day after treatment was started and all were restored to health in less than a week. Apart from a mild to moderate Jarisch-Herxheimer-reaction we didn`t see any side effects of the therapy. Conclusion | LBRF has to be taken into account in feverish patients who come as refugees from East-Africa. It seems that our patients belong to a cluster which probably has its origin in Libya and more patients are to be expected in the near future. As LBRF might cause outbreaks in refugee camps it is pivotal to be aware of this emerging infectious disease in refugees from East-Africa.
authors.forename: M
authors.initials: M
authors.lastname: Seilmaier
authors.forename: W
authors.initials: W
authors.lastname: Guggemos
authors.forename: A
authors.initials: A
authors.lastname: Wieser
authors.forename: V
authors.initials: V
authors.lastname: Fingerle
authors.forename: L
authors.initials: L
authors.lastname: Balzer
authors.forename: T
authors.initials: T
authors.lastname: Fenzl
authors.forename: M
authors.initials: M
authors.lastname: Hoch
authors.forename: U
authors.initials: U
authors.lastname: von Both
authors.forename: H U
authors.initials: HU
authors.lastname: Schmidt
authors.forename: C M
authors.initials: CM
authors.lastname: Wendtner
authors.forename: E
authors.initials: E
authors.lastname: Strobel
mesh_terms: D000293:Adolescent; D000328:Adult; D000349:Africa; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D021821:Communicable Diseases, Emerging / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007303:Insect Vectors / Q000382:microbiology; D008297:Male; D010374:Pediculus / Q000382:microbiology*; D012036:Refugees; D012061:Relapsing Fever / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D004318:Doxycycline